PL1848813T3 - Aktywacja glikolipidem bakteryjnym komórek NKT podlegających restrykcji CD1d - Google Patents

Aktywacja glikolipidem bakteryjnym komórek NKT podlegających restrykcji CD1d

Info

Publication number
PL1848813T3
PL1848813T3 PL06733921T PL06733921T PL1848813T3 PL 1848813 T3 PL1848813 T3 PL 1848813T3 PL 06733921 T PL06733921 T PL 06733921T PL 06733921 T PL06733921 T PL 06733921T PL 1848813 T3 PL1848813 T3 PL 1848813T3
Authority
PL
Poland
Prior art keywords
cd1d
nkt cells
restricted nkt
activation
bacterial glycolipid
Prior art date
Application number
PL06733921T
Other languages
English (en)
Inventor
Luc Teyton
Albert Bendelac
Paul Savage
Original Assignee
Univ Brigham Young
Scripps Research Inst
Univ Chicago
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Brigham Young, Scripps Research Inst, Univ Chicago filed Critical Univ Brigham Young
Publication of PL1848813T3 publication Critical patent/PL1848813T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7032—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • A61K2039/55594—Adjuvants of undefined constitution from bacteria
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
PL06733921T 2005-01-28 2006-01-26 Aktywacja glikolipidem bakteryjnym komórek NKT podlegających restrykcji CD1d PL1848813T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US64815305P 2005-01-28 2005-01-28
PCT/US2006/002781 WO2006083671A2 (en) 2005-01-28 2006-01-26 Bacterial glycolipid activation of cd1d-restricted nkt cells
EP06733921.8A EP1848813B1 (en) 2005-01-28 2006-01-26 Bacterial glycolipid activation of cd1d-restricted nkt cells

Publications (1)

Publication Number Publication Date
PL1848813T3 true PL1848813T3 (pl) 2013-09-30

Family

ID=36777772

Family Applications (1)

Application Number Title Priority Date Filing Date
PL06733921T PL1848813T3 (pl) 2005-01-28 2006-01-26 Aktywacja glikolipidem bakteryjnym komórek NKT podlegających restrykcji CD1d

Country Status (12)

Country Link
US (1) US9295722B2 (pl)
EP (1) EP1848813B1 (pl)
JP (1) JP5053101B2 (pl)
AU (1) AU2006211485B2 (pl)
BR (1) BRPI0607299A2 (pl)
CA (1) CA2593715C (pl)
DK (1) DK1848813T3 (pl)
ES (1) ES2423005T3 (pl)
PL (1) PL1848813T3 (pl)
PT (1) PT1848813E (pl)
WO (1) WO2006083671A2 (pl)
ZA (1) ZA200706208B (pl)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7645873B2 (en) 2003-03-20 2010-01-12 The Scripps Research Institute 6″-amino-6″-deoxygalactosylceramides
CA2661789C (en) 2006-04-07 2014-06-03 The Scripps Research Institute Modified .alpha.-galactosyl ceramides for staining and stimulating natural killer t cells
US7794722B2 (en) * 2006-06-30 2010-09-14 The Scripps Research Institute Adjuvants and methods of use
CA2683681A1 (en) * 2007-04-13 2008-10-23 Academia Sinica Alpha-galactosyl ceramide analogs and their use as immunotherapies
US8916164B2 (en) 2007-08-29 2014-12-23 Abivax Methods of enhancing adjuvaticity of vaccine compositions
AU2013202865B2 (en) * 2007-11-07 2015-03-19 Abivax Increase of immune response and targeting by antigens and/or drug linkage
EP2058011A1 (en) * 2007-11-07 2009-05-13 Wittycell Nkt cell activating gycolipids covalently bound antigens and/or drug
EP2060252A1 (en) 2007-11-19 2009-05-20 Wittycell New formulation of galactosylceramide derivatives
KR101566847B1 (ko) * 2007-12-05 2015-11-06 아비박스 항원에 대한 면역 반응 증강을 위한 글리코실세라마이드의 용도
US9220767B2 (en) * 2008-10-08 2015-12-29 Abivax Vaccine composition for use against influenza
CA2753641C (en) * 2009-02-25 2014-09-16 Supratek Pharma, Inc. Bendamustine cyclopolysaccharide compositions
US8383663B2 (en) 2010-07-19 2013-02-26 Supratek Pharma Inc. Bendamustine anionic-catioinic cyclopolysaccharide compositions
NZ708727A (en) * 2012-12-06 2019-09-27 Victoria Link Ltd Conjugate compounds
US9580758B2 (en) 2013-11-12 2017-02-28 Luc Montagnier System and method for the detection and treatment of infection by a microbial agent associated with HIV infection
JP2023522979A (ja) * 2020-04-23 2023-06-01 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア ｉＮＫＴ細胞の活性化による老化細胞の排除
EP4262997A1 (en) * 2020-12-18 2023-10-25 L'oreal Extract of bacteria of the genus sphingomonas
FR3117776B1 (fr) * 2020-12-18 2024-03-08 Oreal Extrait de bactérie du genreSphingomonas

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5936076A (en) 1991-08-29 1999-08-10 Kirin Beer Kabushiki Kaisha αgalactosylceramide derivatives
TW261533B (pl) 1992-07-16 1995-11-01 Kirin Brewery
JP3717512B2 (ja) 1992-10-22 2005-11-16 麒麟麦酒株式会社 新規スフィンゴ糖脂質およびその使用
US5780441A (en) 1993-04-15 1998-07-14 Kirin Beer Kabushiki Kaisha Sphingoglycolipid compounds and therapeutic uses thereof
CN1125449A (zh) 1993-05-14 1996-06-26 萨依特尔有限公司 作为细胞粘附抑制剂的唾液基Lex类似物
CN1768759A (zh) 1997-04-10 2006-05-10 麒麟麦酒株式会社 神经酰胺化合物在制备细胞活化剂中的应用
JP2001515868A (ja) * 1997-09-12 2001-09-25 ブライハム アンド ウイメンズ ホスピタル Ｃｄ１制限免疫応答のための合成抗原
AU2001252599A1 (en) 2000-04-28 2001-11-12 Orient Cancer Therapy Co., Ltd. Remedies for cancer
AU2002213588A1 (en) * 2000-06-05 2001-12-17 The Brigham And Women's Hospital, Inc. Soluble cd1 compositions and uses thereof
DK1297017T3 (da) * 2000-06-19 2012-09-17 Dana Farber Cancer Inst Inc Sammensætninger og fremgangsmåder med monoklonale og polyklonale antistoffer, der er specifikke for T-cellesubpopulationer
US20020115624A1 (en) * 2000-06-22 2002-08-22 Behar Samuel M. Alpha gylcosylceramides for treating bacterial and fungal infections
AU2002327338A1 (en) * 2001-07-25 2003-02-17 New York University Use of glycosylceramides as adjuvants for vaccines against infections and cancer
KR100549866B1 (ko) * 2001-08-22 2006-02-08 고려대학교 산학협력단 암치료 및 예방 제제
CN1578667A (zh) 2001-11-06 2005-02-09 东方癌症治疗株式会社 抗癌组合物
JP2005533057A (ja) * 2002-06-13 2005-11-04 ニューヨーク・ユニバーシティ 合成ｃ−糖脂質、ならびに癌、感染性疾患および自己免疫疾患を処置するための合成ｃ−糖脂質の使用
US7645873B2 (en) 2003-03-20 2010-01-12 The Scripps Research Institute 6″-amino-6″-deoxygalactosylceramides
CA2519568C (en) 2003-03-20 2012-01-03 Brigham Young University 6"-amino-6"-deoxygalactosylceramides
GB0314682D0 (en) 2003-06-24 2003-07-30 Isis Innovation Materials and methods relating to the modulation of T cell response to soluble antigen
US7998739B2 (en) 2004-09-03 2011-08-16 The Scipps Research Institute Methods of activating NKT cells
CA2661789C (en) 2006-04-07 2014-06-03 The Scripps Research Institute Modified .alpha.-galactosyl ceramides for staining and stimulating natural killer t cells
US7794722B2 (en) 2006-06-30 2010-09-14 The Scripps Research Institute Adjuvants and methods of use

Also Published As

Publication number Publication date
WO2006083671A3 (en) 2007-02-22
BRPI0607299A2 (pt) 2009-08-25
US20080279894A1 (en) 2008-11-13
ZA200706208B (en) 2008-04-30
AU2006211485A1 (en) 2006-08-10
DK1848813T3 (da) 2013-07-15
JP2008528608A (ja) 2008-07-31
WO2006083671B1 (en) 2007-04-12
EP1848813A4 (en) 2008-07-09
PT1848813E (pt) 2013-07-15
ES2423005T3 (es) 2013-09-17
EP1848813B1 (en) 2013-04-10
WO2006083671A2 (en) 2006-08-10
AU2006211485B2 (en) 2011-04-14
US9295722B2 (en) 2016-03-29
CA2593715A1 (en) 2006-08-10
CA2593715C (en) 2015-05-05
EP1848813A2 (en) 2007-10-31
JP5053101B2 (ja) 2012-10-17

Similar Documents

Publication Publication Date Title
EP1848813A4 (en) ACTIVATION OF BACTERIAL GLYCOLIPIDES OF CD1D-DEPLETED NKT CELLS
HK1209648A1 (en) Novel sulfated oligosaccharide derivatives
EP1889172A4 (en) SYSTEM FOR SENDING MESSAGES SPECIFIC TO PATIENTS
SG10201510384UA (en) Cell culture improvements
EP1844380B8 (en) Improvements in or relating to ablutionary installations
GB0613756D0 (en) Cell culture medium
EP2272854A4 (en) NEW GLYCOLIPIDE AND USE THEREOF
ZA200708100B (en) Oligosaccharide mixture
EP1913126A4 (en) Co-culture bioreactor system
ZA201007022B (en) Carbohydrate gel
GB0717796D0 (en) Cell culture chamber
EP2154234A4 (en) TRANSPARENT SOLID SOAP
GB0715183D0 (en) Surfactants not toxic to bacteria
EP2069477A4 (en) CHEMOREPULSION OF CELLS
EP1997884A4 (en) NEW HUMAN T-CELL POPULATION
EP1899910A4 (en) USING MESSAGES TO ENHANCE CRM FUNCTIONALITY
EP2027865A4 (en) LIPOSOME HAVING A LIPIDIC MEMBRANE CONTAINING A BACTERIAL CELLULAR COMPONENT
EP2185684B8 (de) Kollagenhaltiger zellträger
GB0606671D0 (en) Cell Culture
SI1848813T1 (sl) Aktiviranje bakterijskega glikopida s CD1D omenjenih NKT-celic
GB0620265D0 (en) Closed cell
GB0609797D0 (en) Adhesive solution for application to the skin
EP1866071A4 (en) PERMETHYLATION OF OLIGOSACCHARIDES
GB0509318D0 (en) TCR-independent activation of T cells
EP1716857A4 (en) COMPOSITION FOR ACTIVATION OF NKT CELLS